The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

Ozempic has gotten most of the name recognition associated with weight-loss drugs, it's not the only drug in this category ...

Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

Eli Lilly (LLY) is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination that ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...